NEW YORK (GenomeWeb News) – BGI today announced that it has signed a statement of intent with drug giant Merck to explore areas of mutual interest with the goal of "creating value" from the high volume of information resulting from next-generation sequencing technologies.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.